Data / Drug companies / Navinta LLC
Navinta LLC: 20 products in the FDA NDC directory, labeler code 68475
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Navinta LLC (labeler code 68475) lists 20 products in the FDA National Drug Code Directory, covering 15 finished drugs by generic name. By type: 19 prescription drugs, 1 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 11, 2026.
The request: Watch Navinta LLC (FDA labeler code 68475): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68475
- Products in commercial distribution
- 20
- Packages
- 24
- Finished drugs by generic name
- 15
- Prescription products
- 19
- Over the counter products
- 0
- Controlled substance products
- Schedule II 1, Schedule IV 3
- Flagged as original packager
- 18 of 18 products that carry the flag
- Started marketing in the last 12 months
- 7
- Earliest marketing start
- July 23, 2020
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 19 | 95% |
| Bulk ingredients | 1 | 5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 19 | 95% |
| Bulk ingredients | 1 | 5% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Diazepam | 3 | 51 |
| Maraviroc | 2 | 9 |
| Sodium phenylacetate and sodium benzoate | 2 | 7 |
| Sodium phenylbutyrate | 1 | 7 |
| Fomepizole | 1 | 6 |
| Hydralazine hydrochloride | 1 | 47 |
| Glycerol phenylbutyrate | 1 | 8 |
| Trientine hydrochloride | 1 | 7 |
| Carmustine | 1 | 13 |
| Carglumic acid | 1 | 4 |
| Penicillamine | 1 | 12 |
| Miglustat | 1 | 7 |
| Famotidine | 1 | 138 |
| Sevelamer carbonate | 1 | 35 |
| Benztropine mesylate | 1 | 22 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 3 | 15% |
| Gel | 3 | 15% |
| Capsule | 3 | 15% |
| Injection, solution, concentrate | 2 | 10% |
| Injection | 2 | 10% |
| Tablet | 1 | 5% |
| Injection, solution | 1 | 5% |
| Liquid | 1 | 5% |
| Powder | 1 | 5% |
| Kit | 1 | 5% |
| Tablet, for suspension | 1 | 5% |
| Powder, for suspension | 1 | 5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Glycerol Phenylbutyrate | 68475-807 | Liquid | Generic drugs (ANDA) | July 11, 2026 |
| Sodium phenylbutyrate | 68475-011 | Tablet | Generic drugs (ANDA) | July 10, 2026 |
| Diazepam | 68475-804 | Gel | Generic drugs (ANDA) | February 6, 2026 |
| Diazepam | 68475-803 | Gel | Generic drugs (ANDA) | February 6, 2026 |
| Diazepam | 68475-802 | Gel | Generic drugs (ANDA) | February 6, 2026 |
| Sodium phenylacetate and Sodium benzoate | 68475-513 | Injection, solution, concentrate | Generic drugs (ANDA) | December 6, 2025 |
| Hydralazine Hydrochloride | 68475-514 | Injection | Generic drugs (ANDA) | November 25, 2025 |
| Sevelamer carbonate | 68475-010 | Tablet, film coated | Generic drugs (ANDA) | November 1, 2025 |
| Maraviroc | 68475-008 | Tablet, film coated | Generic drugs (ANDA) | June 23, 2025 |
| Maraviroc | 68475-007 | Tablet, film coated | Generic drugs (ANDA) | June 23, 2025 |
| Miglustat | 68475-204 | Capsule | Generic drugs (ANDA) | May 7, 2025 |
| Carglumic acid | 68475-006 | Tablet, for suspension | Generic drugs (ANDA) | August 1, 2022 |
| Penicillamine | 68475-201 | Capsule | Generic drugs (ANDA) | January 1, 2022 |
| Famotidine | 68475-400 | Powder, for suspension | Generic drugs (ANDA) | April 22, 2021 |
| Fomepizole | 68475-510 | Injection, solution | Generic drugs (ANDA) | April 2, 2021 |
| Sodium Phenylacetate and sodium benzoate | 68475-001 | Injection, solution, concentrate | Generic drugs (ANDA) | March 4, 2021 |
| Carmustine | 68475-503 | Kit | Generic drugs (ANDA) | December 29, 2020 |
| Trientine Hydrochloride | 68475-200 | Capsule | Generic drugs (ANDA) | December 5, 2020 |
| Benztropine Mesylate | 68475-512 | Injection | Generic drugs (ANDA) | November 24, 2020 |
| Remifentanil hcl | 68475-021 | Powder | Bulk ingredients | July 23, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.